Table 4.
Target antigens | Diseases | CAR | Vector | NCT no. |
---|---|---|---|---|
GPC3 | Hepatocellular carcinoma | NA | NA | NCT02723942 |
GPC3 | Hepatocellular carcinoma | CD3ζ, CD28, and 4-1BB | NA | NCT02395250 |
GPC3 | Lung squamous cell carcinoma | NA | LV | NCT02876978 |
GPC3 | Hepatocellular carcinoma and liver metastases | 4-1BB | NA | NCT02715362 |
GPC3 | Hepatocellular carcinoma | 4-1BB | NA | NCT03130712 |
GPC3 | Advanced hepatocellular carcinoma | 4-1BB-CD3ζ | RV | NCT03084380 |
GPC3 | Hepatocellular carcinoma, squamous cell lung cancer | NA | NA | NCT03198546 |
GPC3 | Hepatocellular carcinoma | NA | LV | NCT03146234 |
GPC3, mesothelin, CEA | Hepatocellular, pancreatic cancer, colorectal cancer | NA | LV | NCT02959151 |
Mesothelin | Malignant mesothelioma, pancreatic Cancer, ovarian tumor, triple-negative breast cancer, endometrial cancer, other mesothelin-positive tumors | 4-1BB-CD3ζ | RV | NCT02580747 |
Mesothelin | Recurrent or metastatic malignant tumors | NA | NA | NCT02930993 |
Mesothelin | Pancreatic cancer and pancreatic ductal a denocarcinoma | 4-1BB | NA | NCT02706782 |
Mesothelin | Solid tumor, adult advanced cancer | NA | NA | NCT03030001 |
Mesothelin | Advanced solid tumor | NA | NA | NCT03182803 |
EpCAM | Liver neoplasms | NA | NA | NCT02729493 |
EpCAM | Stomach neoplasms | NA | NA | NCT02725125 |
EpCAM | Nasopharyngeal carcinoma and breast cancer | NA | LV | NCT02915445 |
EpCAM | Colon cancer, esophageal carcinoma, pancreatic cancer, prostate cancer, gastric cancer, hepatic carcinoma | CD3ζ, CD28 | LV | NCT03013712 |
GD2 | Neuroblastoma | NA | LV | NCT02765243 |
GD2 | Relapsed or refractory neuroblastoma | NA | NA | NCT02919046 |
GD2 | Solid tumor | NA | LV | NCT02992210 |
HER-2 | Advanced HER-2-positive solid tumors | CD3ζ, 4-1BB-CD3ζ | NA | NCT01935843 |
HER-2 | Breast cancer | CD28-CD3ζ | RV | NCT02547961 |
HER-2 | Breast cancer, ovarian cancer, lung cancer, gastric cancer, glioma, pancreatic cancer | NA | NA | NCT02713984 |
EGFR | Advanced EGFR-positive solid tumors | 4-1BB-CD3ζ | LV | NCT01869166 |
EGFR | Advanced solid tumor | NA | NA | NCT03182816 |
EGFR | Colorectal cancer | 4-1BB-CD28-CD3 | NA | NCT03152435 |
EGFRvIII | Recurrent glioblastoma multiform | NA | LV | NCT02844062 |
EGFRvIII | Glioblastoma multiform | NA | NA | NCT03170141 |
MUC1 | Malignant glioma of brain, colorectal carcinoma, gastric carcinoma | NA | NA | NCT02617134 |
MUC1 | Advanced refractory solid tumor (hepatocellular carcinoma, NSCLC, pancreatic carcinoma, triple-negative invasive breast carcinoma) | CD28-4-1BB- CD3ζ | LV | NCT02587689 |
MUC1 | Advanced solid tumor | NA | NA | NCT03179007 |
CEA | Lung cancer, colorectal cancer, gastric cancer, breast cancer, pancreatic cancer | NA | NA | NCT02349724 |
EphA2 | EphA2-positive malignant glioma | NA | NA | NCT02575261 |
LMP1 | Nasopharyngeal neoplasms | NA | NA | NCT02980315 |
MG7 | Liver metastases | 4-1BB | NA | NCT02862704 |
CD133 | Liver cancer, pancreatic cancer, brain tumor, breast cancer, ovarian tumor, colorectal cancer, ALL, AML | CD3ζ, 4-1BB-CD3ζ | RV | NCT02541370 |
HerinCAR-PD1 | Advanced malignancies | NA | NA | NCT02873390 |
HerinCAR-PD1 | Advanced solid tumor (lung, liver, and stomach) | NA | NA | NCT02862028 |
PD-L1 CSR | Glioblastoma multiform | NA | NA | NCT02937844 |
NY-ESO-1 | Advanced NSCLC | NA | LV | NCT03029273 |
Zeushield | NSCLC | NA | NA | NCT03060343 |
PSCA/MUC1/PD-L1/CD80/86 | Advanced lung or other cancers | NA | NA | NCT03198052 |
PSMA, FRa | Bladder cancer, urothelial carcinoma bladder | NA | NA | NCT03185468 |
Claudin18.2 | Advanced gastric adenocarcinoma, pancreatic adenocarcinoma | NA | LV | NCT03159819 |
CTX cyclophosphamide, FLU fludarabine, LV lentiviral, NA not available, NSCLC non-small cell lung cancer, RV retroviral